Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-04-12
2010-10-19
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07816323
ABSTRACT:
Provided herein is a method for treating cancer in a human by administering a high dose of corticotropin-releasing factor (CRF).
REFERENCES:
patent: 2852054 (1958-09-01), Motley
patent: 4312523 (1982-01-01), Haines
patent: 2003/0061750 (2003-04-01), Bernier et al.
patent: 2006/0163110 (2006-07-01), Adler et al.
patent: WO 2006/021814 (2006-03-01), None
patent: WO 2008/156719 (2008-12-01), None
MedicineNet “Cancer”, accessed from http://www.medterms.com on Jun. 16, 2010, 2 pages.
Sausville et al. Cancer Research, 2006, vol. 66, pp. 3351-3354.
Johnson et al. British J. of Cancer, 2001, 84(10):1424-1431.
Androulidaki et al. Mol. Cancer, 2009, vol. 8, paper No. 30, 12 pages.
Reubi et al. J. Clin. Endocrinol. Metab., 2003, vol. 88, pp. 3312-3320.
Tjuvajev et al. Cancer Research, 1996, vol. 56, pp. 1352-1360.
Vredenburgh et al. Clin. Cancer Res., Feb. 15, 2007, vol. 13, No. 4, pp. 1253-1259.
Arbiser et al., “Corticotrophin-Releasing Hormone Stimulates Angiogenesis and Epithelial Tumor Growth in the Skin,”J. Invest. Dermatology,1999, vol. 113, pp. 838-842.
Avastin® (bevacizumab): Solution for Intravenous Infusion, Product Label, Full Prescribing Information, May 2009.
Carlson et al., “Inhibition of Mouse Melanoma Cell Proliferation by Corticotropin-Releasing Hormone and its Analogs,”Anticancer Res.,2001, vol. 21, pp. 1173-1180.
Carr et al., “The Effect of Corticelin Acetate on Peritumoral Brain Edema: an Interim Report of an Open-label Study as Part of a Phase II Program,”J. Clin. Oncology,2007, ASCO Annual Meeting Proceedings, Part I, vol. 25, No. 18S (Jun. 20 Supplement), Abstract No. 9050.
Graziani et al., “Corticotropin-Releasing Hormone Receptor-1 in Human Endometrial Cancer,”Oncology Reports,2006, vol. 15, pp. 375-379.
Graziani et al., “Evidence that Corticotropin-Releasing Hormone Inhibits Cell Growth of Human Breast Cancer Cells Via the Activation of CRH-R1 Receptor Subtype,”Mol. and Cell. Endocrinology,2007, vol. 264, pp. 44-49.
Hariharan et al, “Phase II Randomized Dose Ranging Trial of Human Corticotropin Releasing Factor in Symptomatic Brain Tumor Patients”, 2000, American Academy of Neurology 52ndAnnual Meeting, Session No. 6, Neuro-Oncology: Clinical Trials, Apr. 30, 2000, Abstract S06.001.
Kesari et al., “Chapter 4: Corticosteroids in Neuro-Oncology”,Cancer Neurology in Clinical Practice: Neurologic Complications of Cancer and Its Treatment,Second Edition, Eds. Schiff et al., Totowa, New Jersey: Human Press, 2008, pp. 47-56.
Minas et al., “Intratumoral CRH Modulates Immuno-Escape of Ovarian Cancer Cells Through FasL Regulation,”British J. Cancer,2007, vol. 97, pp. 637-645.
Moody et al., “Corticoptropin-Releasing Factor Stimulates Cyclic AMP, Arachidonic Acid Release, and Growth of Lung Cancer Cells,” 1994,Pepties,vol. 15, pp. 281-285.
Tjuvajev et al., “Anti-neoplastic Properties of Human Corticotropin Releasing Factor: Involvement of the Nitric Oxide Pathway,” In Vivo, 1998, vol. 12, No. 1, Jan.-Feb. 1998, pp. 1-10.
Villalona-Calero et al., “A Phase I Trial of Human Corticotropin-releasing Factor (hCRF) in Patients with Peritumoral Brain Edema,” Annals of Oncology, 1998, vol. 9, pp. 71-77.
Yang et al., “Enhancement of Cell Migration by Corticotropin-Releasing Hormone Through ERK 1/2 Pathway in Murine Melanoma Cell Line, B16F10,”Experimental Dermatology,2006, vol. 16, pp. 22-27.
Mechtler et al., “Safety and Steroid-Sparing Potential of XERECEPT® (Corticorelin Acetate Injection) for Treatment of Peritumoral Brain Edema: an Interim Report of an Open-Label Study as Part of a Phase III Program”, 2006, 11thAnnual Meeting of the Society for Neuro-Oncology (SNO) Orlando, Florida (Nov. 15-19, 2006) (SNO 2006 Poster).
Mechtler et al., “The Effect of Corticorelin Acetate on Peritumoral Brain Edema: an Interim Report of an Open-Label Study as Part of a Phase III Program”, 2007, 43rdAnnual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Illinois (Jun. 1-5, 2007) (ASCO 2007 Poster).
Recht et al., “Long-Term Safety and Steroid-Sparing Potential of Corticorelin Acetate Injection for Treatment of Peritumoral Brain Edema: Third Interim Report of an Open-Label Study as Part of a Phase III Program”, 2007, 12th Annual Meeting of the Society for Neuro-Oncology (SNO), Dallas, Texas (Nov. 15-18, 2007) (SNO 2007 Poster).
Anderson James D
Jones Day
LandOfFree
Methods of using corticotropin-releasing factor for the use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using corticotropin-releasing factor for the use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using corticotropin-releasing factor for the use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4179903